ZOETIS 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Zoetis reported 3rd quarter 2026 revenue of $2.4 billion, down 1% on both a reported and organic operational basis, driven by a 1% price decline and flat volume.
- Adjusted EPS was $1.75, up 1%, while adjusted net income was $720 million, down 7% on an organic operational basis; GAAP results included a $78 million impairment charge on previously acquired in-process research and development assets.
- U.S. segment revenue was $1.2 billion, down 6%, while international segment revenue was $1.1 billion, up 4%.
- Companion Animal revenue was $1.6 billion, down 5% globally, with an 8% decline in the U.S. and flat performance internationally; key dermatology declined 16% globally to $396 million.
- The Simparica franchise grew 1% globally to $358 million; Companion Animal Diagnostics revenue was $122 million, up 13%; and livestock revenue was $797 million, up 7%.
- Adjusted gross margin was 71%, down 30 basis points on a reported basis and down 60 basis points operationally; adjusted operating expenses were $749 million, flat operationally.
- Zoetis distributed $2.4 billion through the 3rd quarter in 2026 through buybacks and dividends.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the third quarter 2026 financial results conference call and webcast for Zoetis. Hosting the call today is Mathieu Aussermeier, Senior Vice President, Corporate Finance for Zoetis. Presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forward automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. Instructions will be given at that time. It is now my pleasure to turn the call over to Mathieu Aussermeier.
You may begin. Thank you, operator.
Good morning, everyone, and welcome to the Zoetis third quarter 2026 earnings call. I am joined today by Kristin Peck, Chief Executive Officer, and Jay Saccaro, Chief Financial Officer and Chief Operating Officer. This morning, we issued a press release announcing our third quarter 2026 financial results. Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website, and that many of our statements today may be considered forward-looking statements, and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and in our company's Exchange Act reports filed with the SEC. Additionally, today's remarks will include certain non-GAAP financial measures.
Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures can be found in our earnings press release and our company's eight-K filing dated today, November 5th, 2026. We will also reference reported and organic operational growth. Organic operational growth excludes the effect of foreign currency, as well as acquisitions and divestitures, which individually impact Zoetis' growth by 1% or more. Unless otherwise stated, all revenue growth performance metrics will be based on organic operational performance. With that, I will turn the call over to Kristin.
Kristin? Thank you, Matthew. Good morning, everyone, and thank you for joining us.
Today, we reported our third quarter results with revenue and adjusted net income both declining in line with our expectations. Our diversified portfolio provided some resilience, and we focused on defending leadership positions with investments in key franchises. At the same time, we continued advancing the portfolio and innovation pipeline. While challenging dynamics are continuing, we are seeing progress in the actions we are taking and have narrowed our full-year revenue guidance to the high end of our range. As I walk you through our performance, I want to put the industry and company results in perspective and outline how we are positioning Zoetis for the near and long term. But first, I am pleased to welcome Jay to his first earnings call with Zoetis.
He brings a strong track record and a valuable combination of financial and operating experience, and we're excited to have him on the team. With that, let me start with what we see across the industry. As you all know, animal health remains a long-term secular growth industry, driven by a growing global population looking to eat more protein and adopt and care for more pets. Like most industries, however, animal health is not immune to cyclical factors, which affect pet care and livestock differently. In developed pet care markets, veterinary service costs have risen 50% since 2022, well ahead of general inflation. Alongside softer consumer confidence, that cost pressure is making pet owners more value-conscious and deliberate when making trade-offs to care for their pets. The mix of pets is also changing.
High housing costs are affecting homeownership and pet adoption, with fewer dogs joining households as cat ownership continues to grow. Because dogs are more medicalized than cats, this shift also affects underlying demand for veterinary services. These pressures are reflected in the continued weakness in U.S. clinic visits, which are down 3% year to date across categories. These dynamics, combined with intense competition in key franchises, continue to weigh on our companion animal revenue this quarter. At the same time, the bond between people and their pets remains strong. In the U.S., the Human Animal Bond Research Institute's latest survey found that 98% of pet owners experience health benefits from their pets, and 91% said knowing about those benefits makes them more likely to maintain their pet's health. That enduring bond is an important foundation for our industry, but it exists alongside real barriers.
37% of people planning to get a pet cited the cost of ownership as a concern. As the industry leader, we are focused on meeting customers where they are. That means working with veterinary practices to support their profitability and success while developing programs to help pet owners manage the cost of care. In contrast, livestock is benefiting from growing demand for quality protein sources. We're also seeing growing demand on animal health to improve productivity, support food security, and adopt a One Health approach. That demand has contributed to historic industry growth, and for Zoetis, underscores the strength of a broad and diverse portfolio. While we expect livestock to remain a strong contributor over the short, medium, and long term, disease, weather, and local production cycles will continue to influence year-to-year results. Diversity matters, not only across species, but across geographies.
Growth conditions vary significantly from market to market, reflecting differences in economic and geopolitical conditions, species mix, and regulatory environment. In many developed markets, pet care represents a larger and more medicalized share of the animal health market, while in many emerging markets, livestock does. As a result, the same economic shifts can affect markets in very different ways. Tariffs and trade flows continue to evolve, and our commercial strategies reflect the conditions in each market. That local focus matters because emerging markets are expected to remain the fastest-growing part of animal health, with room to bring more animals into regular care, gain share, and broaden access to innovation. Which brings me to what we're doing to defend and grow our leadership.
Building on the actions we've outlined over the past two quarters, today, I'll focus on three priorities: leveraging the diversity of our portfolio, expanding access to established franchises, and advancing innovation. I'll take you through each with examples of how they're showing up across our key franchises. First, we're leveraging the advantage that comes from the diversity and differentiation of our portfolio. Competition is increasingly playing out product by product, but our range of options within the therapeutic categories and across channels gives us more ways to meet customer needs and compete effectively. Those choices are especially important in our key dermatology franchise, where share pressure is most acute. We are continuing to sharpen commercial execution, directing resources where they can influence customer decisions, and reinforcing the value of our differentiated portfolio with vets and pet owners.
For example, we're using that breadth to drive conversion to Apoquel Chew with chew in the room promotion and in-clinic sampling, highlighting a more convenient alternative that can support treatment compliance. At the same time, we expect U.S. approval of long-acting Cytopoint in the fourth quarter, adding a more convenient option for chronic itch, a segment that accounts for more than 60% of global dermatology doses. We're using that added diversity to build awareness for the next option in derm, with a teaser campaign ahead of approval. Similarly, since the beginning of the year, we faced mounting generic competition for Convenia and Cerenia. We acted swiftly, and this quarter, we saw the pace of share gains moderate for the first time since entry.
With recent FDA approval in the U.S. and its coming launch in Canada, Convenia RTU for dogs extends the portfolio with a single injection that can provide up to 14 days of treatment. Second, we're expanding access to our established franchises and investing in the evidence and medical support that help vets navigate a more selective market. When visits are down and owners are weighing the cost of care, the clinical conversation matters. Veterinarians need to identify patients who can benefit and have relevant evidence to support treatment decisions. This is a central role of medical affairs, and one reason we launched the Medical Hub, which houses our scientific insights, publications, and educational materials in one place for veterinary teams. That approach is relevant in parasiticides, where softer end market demand is creating pressure.
Even with double-digit declines in U.S. flea, tick, and heartworm clinic visits, the Simparica franchise delivered modest growth this quarter, as expanded access to Simparica Trio drove growth internationally. Trio's triple combination protection gives vets a differentiated option, supported by recent peer-reviewed research on heartworm resistance. One example of scientific evidence supporting the franchise is a recent peer-reviewed speed of kill study available through the Medical Hub, and our continued investments in phase IV studies provides vets with relevant evidence in a more selective market. We also now expect approval of Simparica Duo by year-end, ahead of our original timeline, broadening the portfolio and extending access to customers with unmet needs. This same strategy applies to OA pain. We're building the category, but it requires sustained effort to improve disease awareness and help veterinarians identify more patients who could benefit from treatment.
We are clear-eyed about the work ahead and measured in our expectations. At the same time, just four years ago, alternatives to NSAIDs were limited. Today, our portfolio offers dogs and cats monthly or longer-acting three-month pain relief. Recent approvals and launches of Lenivia and Portela extend those options, and we believe broader access will build the category over time. These are strong franchises in markets we help build. Our focus is to support customers through current pressures while continuing to invest in their growth. Third, we continue to advance innovation while remaining disciplined in how we allocate capital. In this environment, that means taking costs out where needed to operate more efficiently while protecting investments in innovation and advancing our robust pipeline. Lifecycle innovation is central to the first.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
